See more : Yuhe International, Inc. (YUII) Income Statement Analysis – Financial Results
Complete financial analysis of Chembio Diagnostics, Inc. (CEMI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chembio Diagnostics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Sahathai Terminal Public Company Limited (PORT.BK) Income Statement Analysis – Financial Results
- TheDirectory.com, Inc (SEEK) Income Statement Analysis – Financial Results
- Tourn International AB (publ) (TOURN.ST) Income Statement Analysis – Financial Results
- Itron, Inc. (ITRI) Income Statement Analysis – Financial Results
- Fukuoka Financial Group, Inc. (FKKFF) Income Statement Analysis – Financial Results
Chembio Diagnostics, Inc. (CEMI)
About Chembio Diagnostics, Inc.
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.34M | 36.93M | 30.45M | 34.46M | 33.41M | 24.02M | 17.87M | 24.26M | 27.65M | 29.55M | 25.61M | 19.39M | 16.70M | 13.83M | 11.05M | 9.23M | 6.50M | 3.94M | 3.31M | 0.00 | 0.00 | 0.00 | 1.00 |
| Cost of Revenue | 38.58M | 34.50M | 23.87M | 22.39M | 21.43M | 12.92M | 9.42M | 13.77M | 16.83M | 17.25M | 14.82M | 10.00M | 8.60M | 7.97M | 7.20M | 5.37M | 4.49M | 2.61M | 2.49M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 9.76M | 2.43M | 6.58M | 12.07M | 11.98M | 11.09M | 8.45M | 10.49M | 10.81M | 12.30M | 10.79M | 9.39M | 8.10M | 5.86M | 3.85M | 3.86M | 2.02M | 1.33M | 820.34K | 0.00 | 0.00 | 0.00 | 1.00 |
| Gross Profit Ratio | 20.19% | 6.58% | 21.60% | 35.02% | 35.86% | 46.20% | 47.30% | 43.23% | 39.12% | 41.63% | 42.13% | 48.43% | 48.49% | 42.36% | 34.86% | 41.84% | 31.01% | 33.80% | 24.81% | 0.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 7.07M | 12.49M | 9.51M | 8.54M | 8.53M | 8.56M | 8.43M | 6.38M | 4.83M | 5.83M | 4.49M | 4.88M | 2.59M | 2.88M | 2.61M | 1.91M | 1.40M | 1.36M | 1.43M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.15M | 5.73M | 4.48M | 3.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.28K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.51M | 1.78M | 1.01M | 1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 765.00 | 0.00 | 0.00 |
| SG&A | 24.28M | 24.84M | 21.04M | 16.14M | 11.10M | 9.02M | 7.60M | 7.66M | 7.50M | 5.49M | 4.85M | 3.42M | 2.94M | 2.66M | 3.32M | 4.83M | 5.20M | 3.24M | 2.49M | 3.11K | 45.05K | 6.73K | 128.83K |
| Other Expenses | -1.18M | -10.89M | -2.02M | 0.00 | 0.00 | 0.00 | 0.00 | -4.81K | -5.71K | 7.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 30.16M | 26.44M | 28.53M | 24.68M | 19.63M | 17.58M | 16.02M | 14.04M | 12.36M | 11.30M | 9.34M | 8.30M | 5.53M | 5.54M | 5.92M | 6.74M | 6.61M | 4.63M | 3.92M | 7.12K | 47.02K | 6.73K | 130.77K |
| Cost & Expenses | 68.74M | 60.93M | 52.40M | 47.07M | 41.05M | 30.50M | 25.44M | 27.81M | 29.20M | 28.54M | 24.16M | 18.30M | 14.13M | 13.52M | 13.12M | 12.11M | 11.10M | 7.24M | 6.41M | 7.12K | 47.02K | 6.73K | 130.77K |
| Interest Income | 0.00 | 0.00 | 0.00 | -846.83K | 49.50K | 25.43K | 25.55K | 2.41K | 5.84K | 5.78K | 7.91K | 6.30K | 4.15K | 9.03K | 34.40K | 145.29K | 29.53K | 39.80K | 8.13K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 382.00K | 2.91M | 2.84M | -846.83M | 0.00 | 2.95K | 0.00 | 836.00 | 0.00 | 335.00 | 9.50K | 18.62K | 14.73K | 10.60K | 8.32K | 16.88K | 386.90K | 15.68K | 190.56K | 0.00 | 635.00 | 0.00 | 14.00 |
| Depreciation & Amortization | 5.79M | 2.93M | 2.70M | 721.47K | 337.65K | 1.28M | 1.14M | 1.37M | 739.30K | 607.82K | 523.28K | 437.83K | 283.74K | 362.34K | 345.39K | 283.36K | 209.54K | 98.51K | 109.97K | 4.01K | 367.00 | 63.41K | 176.00 |
| EBITDA | -14.61M | -21.07M | -19.25M | -11.89M | -7.31M | -5.18M | -6.41M | -2.18M | -810.82K | 1.63M | 1.45M | 1.53M | 2.86M | 688.70K | -1.69M | -2.71M | -4.33M | -3.20M | -3.18M | -11.62K | -46.65K | 56.67K | -132.51K |
| EBITDA Ratio | -30.23% | -57.07% | -63.23% | -34.49% | -21.87% | -21.57% | -35.86% | -9.00% | -2.93% | 5.50% | 5.67% | 7.90% | 17.13% | 4.98% | -15.30% | -29.40% | -66.58% | -81.19% | -96.20% | 0.00% | 0.00% | 0.00% | -13,251,300.00% |
| Operating Income | -20.40M | -24.01M | -21.95M | -12.61M | -7.65M | -6.48M | -7.57M | -3.55M | -1.55M | 1.00M | 1.45M | 1.09M | 2.57M | 317.33K | -2.07M | -2.88M | -4.60M | -3.30M | -3.10M | -7.12K | -47.02K | -6.73K | -130.77K |
| Operating Income Ratio | -42.21% | -65.01% | -72.08% | -36.58% | -22.88% | -26.99% | -42.37% | -14.65% | -5.61% | 3.40% | 5.67% | 5.61% | 15.41% | 2.29% | -18.74% | -31.16% | -70.68% | -83.69% | -93.87% | 0.00% | 0.00% | 0.00% | -13,076,900.00% |
| Total Other Income/Expenses | 381.80K | -9.96M | -2.84M | -846.83K | 49.50K | 22.49K | 25.55K | -3.24K | 132.00 | 12.94K | -1.58K | -12.33K | -14.50K | -8.27K | 121.90K | 249.27K | -398.83K | 45.99K | 186.90K | 8.51K | 0.00 | -63.41K | 1.92K |
| Income Before Tax | -23.26M | -33.97M | -25.98M | -14.18M | -7.93M | -6.46M | -7.55M | -3.56M | -1.55M | 1.02M | 1.45M | 1.08M | 2.56M | 309.06K | -1.95M | -2.63M | -5.00M | -3.25M | -2.92M | 1.39K | 0.00 | -70.14K | -128.85K |
| Income Before Tax Ratio | -48.11% | -91.98% | -85.31% | -41.13% | -23.75% | -26.90% | -42.23% | -14.67% | -5.61% | 3.44% | 5.66% | 5.55% | 15.32% | 2.23% | -17.64% | -28.46% | -76.82% | -82.52% | -88.22% | 0.00% | 0.00% | 0.00% | -12,884,900.00% |
| Income Tax Expense | 34.41K | -62.05K | -456.79K | -500.29K | -67.52K | -88.31K | 5.80M | -1.16M | -412.92K | 486.95K | 509.24K | -5.13M | 45.82K | 10.60K | 8.32K | -249.27K | 398.83K | -24.12K | -4.47K | -8.51K | 635.00 | 2.67K | -1.91K |
| Net Income | -23.29M | -33.90M | -25.52M | -13.68M | -7.87M | -6.37M | -13.35M | -2.40M | -1.14M | 530.82K | 941.28K | 6.21M | 2.51M | 309.06K | -1.95M | -2.63M | -5.00M | -3.25M | -3.10M | 1.39K | -47.65K | -72.82K | -128.86K |
| Net Income Ratio | -48.18% | -91.81% | -83.81% | -39.68% | -23.54% | -26.53% | -74.69% | -9.88% | -4.11% | 1.80% | 3.68% | 32.02% | 15.05% | 2.23% | -17.64% | -28.46% | -76.82% | -82.52% | -93.74% | 0.00% | 0.00% | 0.00% | -12,886,400.00% |
| EPS | -0.96 | -1.40 | -1.34 | -0.81 | -0.54 | -0.52 | -1.26 | -0.25 | -0.12 | 0.06 | 0.12 | 0.79 | 0.32 | 0.04 | -0.25 | -1.44 | -3.88 | -3.38 | -4.15 | 0.18 | -5.95 | -35.43 | -115.16 |
| EPS Diluted | -0.96 | -1.40 | -1.34 | -0.81 | -0.54 | -0.52 | -1.26 | -0.25 | -0.12 | 0.06 | 0.11 | 0.73 | 0.32 | 0.03 | -0.25 | -1.44 | -3.88 | -3.38 | -4.15 | 0.18 | -5.95 | -35.43 | -115.16 |
| Weighted Avg Shares Out | 24.30M | 24.30M | 19.09M | 16.95M | 14.43M | 12.30M | 10.62M | 9.63M | 9.53M | 8.99M | 7.99M | 7.87M | 7.76M | 7.74M | 7.66M | 1.83M | 1.29M | 963.22K | 745.85K | 132.89K | 136.19K | 34.94K | 19.02K |
| Weighted Avg Shares Out (Dil) | 24.30M | 24.30M | 19.09M | 16.95M | 14.43M | 12.30M | 10.62M | 9.63M | 9.53M | 9.52M | 8.61M | 8.56M | 8.87M | 9.38M | 7.66M | 1.83M | 1.29M | 963.22K | 745.85K | 132.89K | 136.19K | 34.94K | 19.02K |
Chembio Diagnostics (CEMI) Stock: Why The Price Jumped Today
The stock price of Chembio Diagnostics Inc (NASDAQ: CEMI) increased by over 15% pre-market today. This is why it happened.
Hot Penny Stocks To Buy? 7 To Watch As African Variant Shakes Markets
Hot penny stocks to watch as new virus fears emerge on Black Friday. The post Hot Penny Stocks To Buy?
Chembio Files For FDA Emergency Use Nod For COVID-19 Antigen Test
Chembio Diagnostics Inc (NASDAQ:CEMI) submitted an Emergency Use Authorization (EUA) application to the FDA for the new DPP SARS-CoV-2 Antigen test. The DPP SARS-CoV-2 Antigen test system has been designed to detect COVID-19 antigens in 20 minutes.
Chembio Diagnostics, Inc. (CEMI) CEO Richard Eberly on Q2 2021 Results - Earnings Call Transcript
Chembio Diagnostics, Inc. (CEMI) CEO Richard Eberly on Q2 2021 Results - Earnings Call Transcript
Chembio Diagnostics to Report Third Quarter 2021 Financial Results on November 4, 2021
HAUPPAUGE, N.Y., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter of 2021 after the close of...
Investing in Penny Stocks in September? 3 Strategies to Know
Trading penny stocks in September? You need to know these 3 things The post Investing in Penny Stocks in September?
Hot Penny Stocks to Buy This Month? 3 to Watch Now
Which penny stocks are on your watchlist for next month? The post Hot Penny Stocks to Buy This Month?
Why Chembio Diagnostics Shares Are Trading Higher Today
Chembio Diagnostics Inc (NASDAQ: CEMI) is trading higher Friday after the company announced its launch of commercial distribution of SCOV-2 Ag Detect Rapid Test, a third party COVID-19 antigen assay. Chembio Diagnostics said product inventory is on-hand and immediately available for...
Chembio Starts Distribution of Third-Party COVID-19 Antigen Assay
Chembio Diagnostics Inc (NASDAQ: CEMI) has launched the commercial distribution of an FDA-Emergency Use Authorized rapid point-of-care COVID-19 antigen test. Product inventory is on-hand and immediately available for shipment to Chembio customers across the U.S.
Chembio Launches Commercial Distribution of Third-Party COVID-19 Antigen Assay
HAUPPAUGE, N.Y., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced its launch of commercial distribution of an FDA Emergency Use Authorized, patent pending, rapid point-of-care COVID-19 antigen...
Source: https://incomestatements.info
Category: Stock Reports